Publicaciones en las que colabora con Luis Federico Sanchez Del Campo Ferrer (22)

2023

  1. Targeting protein methylation in pancreatic cancer cells results in KRAS signaling imbalance and inhibition of autophagy

    Cell Death and Disease, Vol. 14, Núm. 11

2021

  1. Acriflavine, a potent inhibitor of HIF-1α, disturbs glucose metabolism and suppresses ATF4-protective pathways in melanoma under non-hypoxic conditions

    Cancers, Vol. 13, Núm. 1, pp. 1-17

  2. MITF induces escape from innate immunity in melanoma

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

2020

  1. PRMT1-dependent methylation of BRCA1 contributes to the epigenetic defense of breast cancer cells against ionizing radiation

    Scientific Reports, Vol. 10, Núm. 1

2016

  1. Lebein, A snake venom disintegrin, Induces apoptosis in human melanoma cells

    Toxins, Vol. 8, Núm. 7

  2. Targeting the epigenetics of the DNA damage response in breast cancer

    Cell Death and Disease, Vol. 7

  3. Tumor suppressor SET9 guides the epigenetic plasticity of breast cancer cells and serves as an early-stage biomarker for predicting metastasis

    Oncogene, Vol. 35, Núm. 47, pp. 6143-6152

2015

  1. Targeting the epigenetic machinery of cancer cells

    Oncogene, Vol. 34, Núm. 2, pp. 135-143

2013

  1. Cómo convertir la resistencia en el talón de Aquiles del melanoma

    Eubacteria, Núm. 32

  2. Directed Phenotype Switching as an Effective Antimelanoma Strategy

    Cancer Cell, Vol. 24, Núm. 1, pp. 105-119

  3. Suppression of antifolate resistance by targeting the myosin Va trafficking pathway in melanoma

    Neoplasia (United States), Vol. 15, Núm. 7, pp. 826-839

2012

  1. Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance

    Experimental Cell Research, Vol. 318, Núm. 10, pp. 1146-1159

2011

  1. Comparison of a Pair of Synthetic Tea-Catechin-Derived Epimers: Synthesis, Antifolate Activity, and Tyrosinase-Mediated Activation in Melanoma

    ChemMedChem, Vol. 6, Núm. 3, pp. 440-449

2010

  1. Mechanism of dihydrofolate reductase downregulation in melanoma by 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin

    Journal of Cellular Biochemistry, Vol. 110, Núm. 6, pp. 1399-1409

  2. Purification and kinetic properties of human recombinant dihydrofolate reductase produced in bombyx mori chrysalides

    Applied Biochemistry and Biotechnology, Vol. 162, Núm. 7, pp. 1834-1846

2009

  1. Binding of natural and synthetic polyphenols to human dihydrofolate reductase

    International Journal of Molecular Sciences, Vol. 10, Núm. 12, pp. 5398-5410

  2. Melanoma activation of 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin to a potent irreversible inhibitor of dihydrofolate reductase

    Molecular Pharmaceutics, Vol. 6, Núm. 3, pp. 883-894

  3. The critical role of alpha-folate receptor in the resistance of melanoma to methotrexate

    Pigment Cell and Melanoma Research, Vol. 22, Núm. 5, pp. 588-600

2008

  1. Synthesis and biological activity of a 3,4,5-trimethoxybenzoyl ester analogue of epicatechin-3-gallate

    Journal of Medicinal Chemistry, Vol. 51, Núm. 7, pp. 2018-2026

  2. Targeting the methionine cycle for melanoma therapy with 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin

    International Journal of Cancer, Vol. 123, Núm. 10, pp. 2446-2455